Results 31 to 40 of about 4,378 (171)

Nucleation‐Controlled Reconstruction of CuOx for Selective CO2 Electroreduction

Advanced Functional Materials, EarlyView.
The ratio of oxygen vacancies (Ov) and exposed Cu2O (111)/(200) of CuOx precatalyst is modulated by nucleation control of Cu(OH)2 precursor. Low Ov ratio and high ratio of Cu2O (111)/(200) in slow‐nucleated CuOx reconstructs to high‐coordinated oxide‐derived copper (OD‐Cu) during electrochemical CO2 reduction reaction (CO2RR) and exhibits enhanced ...
Ying Ying Ch'ng, Zhipeng Ma, Ming Zhang, Shujie Zhou, Varun Kundi, Priyank Vijaya Kumar, Wenyu Zhong, Yuwei Yang, Jitraporn Vongsvivut, Qinfen Gu, Xiaoxuan Luo, Lixue Jiang, Rahman Daiyan, Zhaojun Han, Rose Amal   +14 more
wiley   +1 more source

Retrospective Toxicological Profiling of Radium-223 Dichloride for the Treatment of Bone Metastases in Prostate Cancer Using Adverse Event Data

Medicina, 2019
Background and Objective: Radium-223 dichloride (Xofigo®) is a calcium mimetic agent approved for the treatment of castration-resistant prostate cancer patients with symptomatic bone metastases and no known visceral metastatic disease. This targeted,
Theodoros G. Soldatos, Ioannis Iakovou, Christos Sachpekidis   +2 more
doaj   +1 more source

The Curies’ element: state of the art and perspectives on the use of radium in nuclear medicine

EJNMMI Radiopharmacy and Chemistry, 2023
Background The alpha-emitter radium-223 (223Ra) is presently used in nuclear medicine for the palliative treatment of bone metastases from castration-resistant prostate cancer.
Sara Franchi, Mattia Asti, Valerio Di Marco, Marianna Tosato   +3 more
doaj   +1 more source

Strategies for Loading and Releasing Peptide Therapeutics in Biodegradable Carriers

Advanced Functional Materials, EarlyView.
A biodegradable carrier‐based peptide delivery system is a powerful treatment platform for diverse diseases, owing to its superior therapeutic efficacy and low toxicity. This review examines the conventional peptide‐loaded carrier fabrication process and its current limitations.
Wookyoung Jang, Ki Wan Bong
wiley   +1 more source

Lattice Structures for Bone Replacement: The Intersection of Bone Biomechanics, Lattice Design, and Additive Manufacturing

Advanced Materials Technologies, EarlyView.
This review outlines how understanding bone's biology, hierarchical architecture, and mechanical anisotropy informs the design of lattice structures that replicate bone morphology and mechanical behavior. Additive manufacturing enables the fabrication of orthopedic implants that incorporate such structures using a range of engineering materials ...
Stylianos Kechagias, Maxwell J. Munford, Frederik C.H. Masure, Richard J. van Arkel, Reece N Oosterbeek   +4 more
wiley   +1 more source

T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities

Advanced Science, EarlyView.
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu, Xiaoyu Yao, Qingyang Wang, Mengrui Yang, Runze Li, Jiangjiang Qin, Jing Zhuang, Changgang Sun   +7 more
wiley   +1 more source

An Implantable Scaffold Sequentially Releasing STING Agonist and B7‐H3 Antibody for Bone Metastasis Immunotherapy

Advanced Science, EarlyView.
We developed an implantable dual‐drug depot using GelMA for bone metastasis treatment, co‐delivering MSA‐2 and αB7‐H3‐loaded CaCO3 microparticles. Sustained release from GelMA scaffold enables MSA‐2 to activate STING signaling and enhance T‐cell infiltration and activation, while sequentially released αB7‐H3 blocks MSA‐2‐induced B7‐H3 upregulation ...
Qijun Lin, Hong Xiao, Shuai Fan, Kaimin Cai, Yanteng Xu, Xinwen Wang, Guanhong Chen, Chuandong Lang, Xinsheng Peng, Mingqiang Li, Yuhu Dai   +10 more
wiley   +1 more source

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program

BMC Cancer, 2019
Background Radium-223, a targeted alpha therapy, is used to treat symptomatic patients with castration-resistant prostate cancer (CRPC) and bone metastases. Data for radium-223 in asymptomatic CRPC patients with bone metastases are lacking.
Axel Heidenreich, Silke Gillessen, Daniel Heinrich, Daniel Keizman, Joe M. O’Sullivan, Joan Carles, Manfred Wirth, Kurt Miller, John Reeves, Monica Seger, Sten Nilsson, Fred Saad   +11 more
doaj   +1 more source

Extracellular Vesicles in Autoimmune Diseases: From Diagnostic Biomarkers to Engineered Therapeutics

Advanced Science, EarlyView.
This review provides a systematic comparison of extracellular vesicles (EVs) from both mammalian and plant sources in the context of autoimmune diseases. It highlights their emerging roles as precision biomarkers and engineered therapeutic platforms.
Yufei Wu, Huiyuan Ma, Tinghui Zhu, Shuwei Huang, Manxi Lu, Qiong Wang, Zai‐Long Chi   +6 more
wiley   +1 more source

Therapeutic Gases in Biomedicine: Updates on Nitric Oxide and Beyond

Advanced Science, EarlyView.
Therapeutic gases, including NO, CO, H2S, H2, CO2, O2, and Xe, play vital roles in cellular signaling and repair. This review highlights the emerging carriers and delivery systems that enable controlled, localized gas release for diagnostic and therapeutic applications.
Syed Muntazir Andrabi, Navatha Shree Sharma, Imran Ibn Gani Rather, S. M. Shatil Shahriar, Jingwei Xie   +4 more
wiley   +1 more source